Brief: Morgan Stanley's Long Position Shanghai Henlius Biotech H-Shares Reduces To 1.04% On Sept 3 - HKEX
09/09/2024 13:57
Sept 9 (Reuters) -
* MORGAN STANLEY'S LONG POSITION IN H-SHARES OF SHANGHAI
HENLIUS
BIOTECH 2696.HK DECREASES TO 1.04% ON SEPT 3 FROM 5.77% - HKEX
Further company coverage: 2696.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Shanghai Henlius Biotech
See all newsBrief: Shanghai Henlius Biotech Says Wenjie Zhang Resigns As Chairman
Brief: Shanghai Henlius Biotech Enters Collaboration And License Agreement With Amberstone Biosciences
Brief: Shanghai Henlius Biotech Says NDA For 120 Mg Biosimilar Denosumab HLX14 Accepted By NMPA
China's Henlius H1 revenue jumps on drug sales, license income
Brief: Shanghai Henlius Biotech Logs HY Profit RMB 430.4 Mln